rivastigmine sandoz 9,5 mg/24 h system transdermalny, plaster
sandoz gmbh - rivastigminum - system transdermalny, plaster - 9,5 mg/24 h
emerpand 9,5 mg/ 24 h system transdermalny, plaster
actavis group ptc ehf. - rivastigminum - system transdermalny, plaster - 9,5 mg/ 24 h
rubraca
pharmaand gmbh - rucaparib camsylate - nowotwory jajnika - Środki przeciwnowotworowe - rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. rubraca jest wskazany w monoterapii w leczeniu dorosłych pacjentów z платиночувствительный nawrotu wysokiej jakości nabłonka jajnika, jajowodu lub pierwotnym перитонеальным na raka, którzy w odpowiedzi (pełny lub częściowy) na bazie platyny chemioterapii.
imatinib actavis
actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. efekt imatinib na wynik przeszczepienia szpiku kostnego nie jest określona. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. doświadczenie z imatinibom u pacjentów z mds/jest msy, związanych z pdgfr genów permutacji-bardzo ograniczony. brak kontrolowanych badań wykazują kliniczną korzyść lub zwiększone tempo dla tych chorób.
olanzapin krka 10 mg tabletki
krka, d.d., novo mesto - olanzapinum - tabletki - 10 mg
olanzapin krka 15 mg tabletki
krka, d.d., novo mesto - olanzapinum - tabletki - 15 mg
olanzapin krka 20 mg tabletki
krka, d.d., novo mesto - olanzapinum - tabletki - 20 mg
calgel (3,3 mg + 1 mg)/g Żel do stosowania na dziąsła
mcneil healthcare (ireland) limited - lidocaini hydrochloridum + cetylpyridinii chloridum - Żel do stosowania na dziąsła - (3,3 mg + 1 mg)/g
hemoroidal (50 mg + 5 mg)/g Żel doodbytniczy
poznańskie zakłady zielarskie "herbapol" s.a. - hippocastani corticis extractum siccum + lidocaini hydrochloridum monohydricum - Żel doodbytniczy - (50 mg + 5 mg)/g
olanzapin krka 5 mg tabletki
krka, d.d., novo mesto - olanzapinum - tabletki - 5 mg